[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341818-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341818-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-landscape-of-gastric-cancer-targeted-therapy-and-identification-of-csnk2a1-as-a-potential-target","Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target","","Objective: conduct a comprehensive analysis of gastric cancer (GC)-targeted therapy clinical trial landscape and identify potential therapeutic targets. Methods: systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL) retrieved GC clinical trials published up to June 30, 2022; approved targets for 11 cancers were compiled; CSNK2A1 in GC was assessed via multiple bioinformatics tools and functional experiments. Results: GC randomized controlled trials showed a 74.29% failure rate (26/35). CSNK2A1 upregulation associated with increased sensitivity to CX-4945, with apoptosis confirmed by flow cytometry and Western blot. Conclusions: CSNK2A1 is a promising GC target and may serve as a biomarker, pending further mechanistic and clinical validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-landscape-of-gastric-cancer-targeted-therapy-and-identification-of-csnk2a1-as-a-potential-target/341818/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-landscape-of-gastric-cancer-targeted-therapy-and-identification-of-csnk2a1-as-a-potential-target/341818.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study?","Question",{"text":63,"@type":64},"To comprehensively analyze the landscape of gastric cancer (GC)-targeted therapy clinical trials and identify potential therapeutic targets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were clinical trials and therapeutic targets collected and analyzed?",{"text":68,"@type":64},"A systematic search of CENTRAL retrieved GC clinical trials published up to June 30, 2022, and approved therapeutic targets for 11 common cancers were compiled and analyzed.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is CSNK2A1 proposed as a potential therapeutic target for GC?",{"text":72,"@type":64},"Bioinformatics linked CSNK2A1 to multiple GC biological characteristics, its increased expression correlated with greater sensitivity to CX-4945, and experiments showed concentration-dependent apoptosis after CX-4945 treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341818,1790114211,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Heliyon 10 (2024) e36205  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \nResearch article  \nComprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target  \nLiang Zhang a, b, 1 , Jiaqi Yanga, 1 , Yingpeng Huang a , Tao You a , Qunjia Huang a , Xian Shenc , Xiangyang Xuea, b, ** , Shiyu Feng b, *  \na Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China  \nb Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-Related Pathogens and Immunity, Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China  \nc Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China  \nA R T I C L E I N F O  \nKeywords:  \nGastric cancer Targeted therapy Biomarker CSNK2A1  \nApoptosis  \nA B S T R A C T  \nObjective: To conduct a comprehensive analysis of the landscape of gastric cancer (GC)-targeted therapy clinical trials and identify potential therapeutic targets.  \nMethods: A systematic search and analysis of the Cochrane Central Register of Controlled Trials (CENTRAL) was performed to retrieve all GC clinical trials published up to June 30, 2022. Approved therapeutic targets for 11 common cancers were compiled and analyzed. The role of CSNK2A1 in GC was investigated using bioinformatics tools such as GEPIA, KMPLOT, SangerBox, STRING, ACLBI, and TIMER. Four gastric cancer cell lines (AGS, HGC, MGC, BGC) and one normal gastric mucosa cell line (GES-1) were utilized to assess the sensitivity to the CSNK2A1 inhibitor CX-4945. Quantitative real-time polymerase chain reaction (qPCR) was employed to quantify the cellular expression of CSNK2A1. Cellular apoptosis was evaluated using flow cytometry and Western blot analysis.  \nResults: The failure rate of GC randomized controlled clinical trials (RCTs) was strikingly high, accounting for 74.29 %(26/35) of the trials. Among the 35 approved targets in 11 different cancers, 13 targets were rigorously evaluated and identified as potential therapeutic targets for GC. Bioinformatics analysis revealed that CSNK2A1 is closely associated with multiple biological characteristics in GC, and its increased expression correlated significantly with enhanced sensitivity to CX-4945 treatment. Flow cytometry and Western blot analysis consistently demonstrated concentration-dependent apoptosis induced by CX-4945 in GC cell lines.  \nConclusions: The high failure rate of GC clinical trials highlights the need for a more scientific and precise approach in target identification and clinical trial design. CSNK2A1 emerges as a promising therapeutic target for GC, and its expression level could potentially serve as a biomarker for  \n* Corresponding author. Microbiology and Immunology Laboratory, Basic Medicine College of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China.  \n** Corresponding author. Microbiology and Immunology Laboratory, Basic Medicine College of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China.  \n[E-mail addresses:](E-mail addresses: wzxxy001@163.com)[ wzxxy001@163.com](E-mail addresses: wzxxy001@163.com) (X. Xue), [Plingzj1998@163.com](Plingzj1998@163.com) (S. Feng).  \n1 Liang Zhang and Jiaqi Yang contributed equally to this work.  \n[https://doi.org/10.1016/j.heliyon.2024.e36205](https://doi.org/10.1016/j.heliyon.2024.e36205)  \nReceived 3 April 2024; Received in revised form 11 August 2024; Accepted 12 August 2024 Available online 18 August 2024  \n2405-8440/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC ","cbCaiopZZrjJfgoJ","https://ap.wps.com/l/cbCaiopZZrjJfgoJ","pdf",10165021,11,"English","# Introduction\n## Targeted therapy and therapeutic target limitations in GC\n# Methods\n## Clinical trial landscape retrieval and target compilation\n## Bioinformatics and CSNK2A1 functional validation\n# Results\n## Failure rate of GC randomized controlled trials\n## CSNK2A1 links to GC features and CX-4945 sensitivity\n## CX-4945 induces concentration-dependent apoptosis\n# Conclusions\n## Need for improved precision in target identification and trial design","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To comprehensively analyze the landscape of gastric cancer (GC)-targeted therapy clinical trials and identify potential therapeutic targets.\"},{\"question\":\"How were clinical trials and therapeutic targets collected and analyzed?\",\"answer\":\"A systematic search of CENTRAL retrieved GC clinical trials published up to June 30, 2022, and approved therapeutic targets for 11 common cancers were compiled and analyzed.\"},{\"question\":\"Why is CSNK2A1 proposed as a potential therapeutic target for GC?\",\"answer\":\"Bioinformatics linked CSNK2A1 to multiple GC biological characteristics, its increased expression correlated with greater sensitivity to CX-4945, and experiments showed concentration-dependent apoptosis after CX-4945 treatment.\"}]","Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target | PDF",1790043977,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83fa8f527af2b535317c9b12b378e604.webp",983,1341,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f1eb0d3f41644324c722cf873709f42.webp",982,1340,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0b3defff7678d33cbce4dc187b1e53a.webp",981,1338,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07e2606ae29bc88e0b66792fd0116b93.webp",980,1337]